About BMC

Company Profile
BMC Medical Co., Ltd.
(“BMC”, 301376.SZ)

BMC devotes in respiratory healthcare over 20 years, partner with families worldwide to overcome the discomfort of chronic respiratory disease with quality products, professional services, and proactive care, aimed to become the first choice in respiratory care.

Market Distribution
No.2 in the World, No.1 in China
CPAP devices sales: Ranked 2nd globally, the only Chinese company among the global top 5.
3
M+
CPAP&BPAP device sold globally
10
M+
CPAP masks sold globally
10
M+
Patient service
140
+
Countries and regions covered
Certifications

Over 20 products have been certified by the U.S. Food and Drug Administration (FDA). We are the only Chinese CPAP brand with FDA-certified products that are genuinely sold in the United States, ranking second in U.S. market share. We are also the first Chinese medical device company to successfully respond to a U.S. Section 337 investigation.

Innovations and Patents
930
+
Patents
260
+
Foreign Patents
38
Industrial Standards
Led ISO 80601-2-90:2021

World's 1st international standard for COVID-19 & acute respiratory diseases.

Data-Driven Cloud Management From
Compliance to Confidence

PAP Link Digital Health solution, comprising Web, PC and APP versions, provides you with a complete set of tools to increase efficiencies by streamlining workflows, drive better patient outcomes through systematic management, and boost their therapy comfort.

Development History
2001-2007
2008-2013
2014-2017
2018-2021
2022-2024
2025–Present
2001-2007

    · YiheJiaye(BMC) established.

    · Core team formed.

    · Launched the first-generation sleep diagnostic product and CPAP device.


2008-2013

    · Obtained CE certification, enabling entry into global market.

    · Completed Series A financing of RMB 8M.

    · Launched the G1 BPAP series.

    · Obtained FDA clearance and officially entered the U.S. market.

    · Established the first Sleep & Respiratory Health Experience Center.

2014-2017

    · Established Shenzhen R&D Center.

    · Established BMC (Tianjin) Medical Co., Ltd.

    · Completed Series B financing of RMB 60M.

    · Launched the Respiratory Health Data Cloud Platform.

    · Successfully addressed the U.S. Section 337 investigation.

2018-2021

    · Established the first Customer Service Center.

    · Completed Pre-IPO financing of RMB 37M, preparing for capital market entry.

    · Launched the globally best-selling G3 BPAP series and 1st-generation medical ventilators.

    · CPAPs production exceeded 1 million units.

2022-2024

    · Listed on Shenzhen ChiNext (301367.SZ).

    · Established Dongguan Production Base.

    · Launched oxygen concentrators and medical cylinders, officially entering the oxygen therapy market.

    · Established subsidiaries in France (BMC Medical France SARL) and Hong Kong.

    · Launched E5/P5 CPAP series.

2025–Present

    · Renamed to BMC Medical Co., Ltd.(formerly "YiheJiaye"), achieving unified corporate, securities, and brand naming.

    · Launched E5/P5 CPAP for pulmonary diseases.

    · Launched the KO1 portable oxygen concentrator, building a smart oxygen therapy branch.

Our website use cookies to enhance your experience. By continuing to browse, you agree to the use of our own and third-party cookies as detailed in our Cookie.
Accept Reject